Avidity Biosciences, Inc.
Net SellingRNA·US·🇺🇸 US
5%buys·95%sales
494 transactions$84.6MTotal buys·8 buys
$103.1MTotal sells·142 sells
2727 insiders
Last: Dec 19, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Dec 19, 25 | LEVIN ARTHUR A | Gift | - | |
| Dec 18, 25 | Boyce Sarah | Gift | - | |
| Dec 17, 25 | McCarthy Teresa | Other | $1.2M | |
| Dec 17, 25 | McCarthy Teresa | Grant | - | |
| Dec 17, 25 | Gallagher Kathleen P. | Other | $2.4M | |
| Dec 17, 25 | Gallagher Kathleen P. | Other | $577K | |
| Dec 17, 25 | Gallagher Kathleen P. | Grant | - | |
| Dec 17, 25 | Moriarty John B | Grant | - | |
| Dec 17, 25 | Moriarty John B | Other | $1.9M | |
| Dec 17, 25 | Boyce Sarah | Other | $1.1M |
Avidity Biosciences, Inc. (RNA) has recorded 494 insider transactions from 27 insiders. Total insider buying volume stands at $84.6M, while total selling volume is $103.1M. Overall insider sentiment is bearish (95% sales).
Avidity Biosciences, Inc. (RNA) has recorded 494 insider operations, including 8 open-market purchases ($84.6M), 142 sales ($103.1M) and 344 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (95% sales).
Insider activity at Avidity Biosciences, Inc. is sustained, with operations recorded in 10 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are Boyce Sarah (CEO), MacLean Michael F (CFO) & LEVIN ARTHUR A (C SUITE), with respectively 135, 99, 173 transactions.
Across all 494 recorded transactions, the breakdown by type is: exercise (200, 40%), sales (142, 29%), grant (123, 25%), tax (9, 2%), buys (8, 2%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Avidity Biosciences, Inc. has recorded 494 insider operations in total, including 8 open-market purchases ($84.6M), 142 sales ($103.1M) and 344 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on December 19, 2025.
Insiders at Avidity Biosciences, Inc. are currently net sellers, with 5% purchases and 95% sales across all reported transactions. Total buy volume is $84.6M versus $103.1M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 27 insiders at Avidity Biosciences, Inc. (RNA). Boyce Sarah (CEO, 135 tx), MacLean Michael F (CFO, 99 tx), LEVIN ARTHUR A (C SUITE, 173 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for RNA is bearish, based on a 5% buy ratio across 150 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Avidity Biosciences, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.